Scibids Helps Charlotte Tilbury Beauty Reduce Cost Per Acquisition (CPA) by 29% With Custom Bidding
Within two months the beauty brand saw a 60% increase in conversion rate and doubled…
News
Schneider Electric’s Award-Winning Square D Energy Center Now Available for Order
Smartest, most-awarded panel on the market now available for order from electrical distribution centers Innovative…
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass.,…
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
– AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma– AUTO1/22: oral…
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — In a release issued under the same…
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed…
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells…
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine…
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical…
Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress
Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th…
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of…
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients…
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1…
Invectys appoints Timothy Papp as its Chief Financial Officer
Houston, Texas, USA, May 12, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston, Texas, a…
Better Choice Company Board of Directors Authorize Stock Repurchase Program
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE: BTTR) (the…
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first…
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a…
Backblaze Launches Channel Partner Program
Combines new Channel Partner team with a package of benefits, rewards, and resources to ease…